Singapore: CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Yuhan, a leading manufacturer of pharmaceutical products based in Seoul, South Korea announced the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins.

CAP-T CAP cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior protein yields in a shorter time frame than traditional methods.

"With Yuhan we have won one-of-the-most prestigious Asian pharma companies as a customer. We're very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules. I am convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases " stated Mr Wolfgang Kintzel, CEO, CEVEC.

Dr Jong-Gyun Kim, head, bio-innovation unit, Yuhan Research Institute, said that, "After evaluating CAP and CAP-T we are excited about the potential of CEVEC's CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it's authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."